首页 正文

Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis

{{output}}
Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients' quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis... ...